← All candidates
Seven insider buys in the last year — $25.18M in all.
21 filings on record.
BLSMBlossomHill Therapeutics, Inc.
NasdaqGS · Healthcare · $763.38M
$26.25
+18.40% today
Seven insider buys in the last year — $25.18M in all.
Nothing in the last fortnight.
Price · 1Y · daily● 7 buys◆ 2 8-K
▸ hover a marker for the filing · drag to zoom · daily bars sharpen to 30-min on close ranges · 1 move explained
AI brief · from the filings on this pagePro
The filings, the score and the setup on this page, read for you in about ten seconds — what the insiders did, and what stands against it.
Market cap
$763.38M
Float
1.4M
5% public
Short % float
Pro
The buyers
▸ each insider's past open-market buys, measured ~6 months (120 trading days) later, against the S&P over the same spans · split-adjusted · pre-scheduled 10b5-1 plan trades excluded · past outcomes, not predictions
Director
Gordon Carl L
Bought $10.00M on Aug 10 — 625,000 sh @ $16.00, held indirect, 23% of their stake.
First Form 4 on file
Director
Orbimed Advisors LLC
Bought $10.00M on Aug 10 — 625,000 sh @ $16.00, held indirect, 23% of their stake.
First Form 4 on file
10% owner
Chen Bihua
Bought $5.00M on Aug 10 — 312,500 sh @ $16.00, held indirect, 8.6% of their stake.
First Form 4 on file
Institutional stakes
▸ a holder crossing 5% files Schedule 13D if they intend to act on the company, 13G if they certify they will not · /A amends an earlier filing
4 filingsnewest first
The record
newest first
DateTypeInsiderOf stakeShares @ priceValue
16 more transactions on Pro →Context
Wall St
$32.20 avg target
+22.7% vs today · 5 analysts · consensus Strong Buy
▸ relayed analyst opinion, which tends to run optimistic — not our forecast or advice
The file stays open
21 filings on record.
The next one will be too.
▸ SEC EDGAR · FINRA · Nasdaq — public sources only · research, not advice